LivaNova - Page title

Press Releases

Oct 03, 2019

LivaNova to Host Conference Call for Third Quarter 2019 Results

  LONDON --(BUSINESS WIRE)--Oct. 3, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2019 results on Wednesday, October 30, 2019 at 12 p.m.   London time ( 8 a.m. Eastern Daylight Time )....Read More
Sep 27, 2019

LivaNova Enrolls First Patient in RECOVER Clinical Study

  LONDON --(BUSINESS WIRE)--Sep. 27, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient enrolled in “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem o nstrating the Safety and Effectiveness of V...Read More
Sep 13, 2019

LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

LONDON --(BUSINESS WIRE)--Sep. 13, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the...Read More
Sep 05, 2019

LivaNova Receives Approval from U.S. Centers for Medicare & Medicaid Services for RECOVER Clinical Study

Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program LONDON --(BUSINESS WIRE)--Sep. 5, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and...Read More
Aug 30, 2019

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2019

LONDON --(BUSINESS WIRE)--Aug. 30, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present two abstracts further establishing the viability of implantable neuromodulation technology to treat patients with heart failure during...Read More
Jul 31, 2019

LivaNova Reports Second Quarter 2019 Results

LONDON --(BUSINESS WIRE)--Jul. 31, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2019 . For the second quarter of 2019, worldwide sales from continuing operations were $277.2 million , a decrease...Read More
Jul 16, 2019

LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula

CE Marked Bi-Flow is the only cannula designed to prevent leg ischemia during cardiac procedures requiring femoral artery cannulation LONDON --(BUSINESS WIRE)--Jul. 16, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral...Read More
Jul 15, 2019

LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System

The versatile and compact system offers the power and simplicity to support more patients in more places LONDON --(BUSINESS WIRE)--Jul. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S....Read More
Jul 11, 2019

LivaNova Celebrates 25 Years of Vagus Nerve Stimulation Therapy

Revolutionary therapy system has treated more than 120,000 patients worldwide LONDON --(BUSINESS WIRE)--Jul. 11, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, is celebrating the 25th anniversary of its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System....Read More
Jun 19, 2019

LivaNova Welcomes Stacy Enxing Seng to Board of Directors

LONDON --(BUSINESS WIRE)--Jun. 19, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stacy Enxing Seng , a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the...Read More
Jun 17, 2019

LivaNova to Host Conference Call for Second Quarter 2019 Results

LONDON --(BUSINESS WIRE)--Jun. 17, 2019-- LivaNova PLC  (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on  Wednesday, July 31, 2019 at  1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More
May 23, 2019

LivaNova to Present at the Jefferies Healthcare Conference

LONDON --(BUSINESS WIRE)--May 23, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, and Thad Huston , Chief Financial Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4 in New York...Read More
May 16, 2019

LivaNova to Present at the UBS Global Healthcare Conference

LONDON --(BUSINESS WIRE)--May 16, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, and Thad Huston , Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New...Read More
May 03, 2019

New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting

Key findings from study at Leuven University Hospital show no explants due to structural valve deterioration in 11 years of Perceval use LONDON --(BUSINESS WIRE)--May 3, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that new clinical data for its...Read More
May 01, 2019

LivaNova Reports First Quarter 2019 Results

LONDON --(BUSINESS WIRE)--May 1, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2019 . For the first quarter of 2019, worldwide sales from continuing operations were $250.8 million , an increase...Read More
Apr 05, 2019

LivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results

LONDON --(BUSINESS WIRE)--Apr. 5, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019 . Preliminary First Quarter 2019 Results The Company expects worldwide sales from continuing...Read More
Apr 01, 2019

LivaNova to Present at the Needham Healthcare Conference

LONDON --(BUSINESS WIRE)--Apr. 1, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer of LivaNova , will present at the Needham Healthcare Conference on Tuesday, April 9 in New York at 2:10 p.m....Read More
Mar 29, 2019

LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device

LONDON --(BUSINESS WIRE)--Mar. 29, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device....Read More
Mar 18, 2019

LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer

LONDON --(BUSINESS WIRE)--Mar. 18, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team...Read More
Mar 15, 2019

LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session

LONDON --(BUSINESS WIRE)--Mar. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology...Read More
Feb 27, 2019

LivaNova Reports Fourth Quarter and Full-Year 2018 Results

LONDON --(BUSINESS WIRE)--Feb. 27, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018 . For the fourth quarter of 2018, worldwide sales were $297.0 million , an increase of 6.7...Read More
Feb 25, 2019

LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform

New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions LONDON --(BUSINESS WIRE)--Feb. 25, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve...Read More
Feb 21, 2019

LivaNova’s Perceval Sutureless Aortic Heart Valve Receives National Reimbursement in Japan to Treat Patients with Aortic Valve Disease

LONDON --(BUSINESS WIRE)--Feb. 21, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval ® sutureless aortic heart valve to treat aortic valve...Read More
Feb 15, 2019

LivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression

Company plans to submit clinical study protocol for CMS consideration LONDON --(BUSINESS WIRE)--Feb. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage...Read More
Jan 28, 2019

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2018 Results

LONDON --(BUSINESS WIRE)--Jan. 28, 2019-- LivaNova PLC  (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on  Wednesday, Feb. 27, 2019 at  1 p.m. London time ( 8 a.m. Eastern Standard Time )....Read More
Jan 17, 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON --(BUSINESS WIRE)--Jan. 17, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies...Read More